Detalhe da pesquisa
1.
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.
Antimicrob Agents Chemother
; 66(6): e0013222, 2022 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35607978
2.
The Africa non-communicable diseases (NCD) Open Lab: Impact of a portfolio of clinical studies to deepen the understanding of NCDs in sub-Saharan Africa.
J Glob Health
; 14: 04065, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695258
3.
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Nat Med
; 30(3): 896-904, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38365949
4.
Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin.
Pharmaceutics
; 14(8)2022 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35893785
5.
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.
Int J Geriatr Psychiatry
; 26(5): 536-44, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20872778
6.
Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
J Alzheimers Dis
; 14(3): 301-11, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18599956
7.
A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease.
Alzheimers Dement (N Y)
; 1(2): 131-140, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29854933
8.
Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease.
Alzheimers Dement (N Y)
; 1(1): 23-36, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29854923